Wird geladen...
Multicentre experience of home omalizumab treatment for chronic spontaneous urticaria
INTRODUCTION: Due to perceived risk of anaphylaxis, home treatment with omalizumab has been limited. Within the UK, most centres administer omalizumab in a hospital setting. However, the reported prevalence of anaphylaxis is low and in December 2018 home treatment became licensed. A home treatment p...
Gespeichert in:
| Veröffentlicht in: | Eur J Hosp Pharm |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
BMJ Publishing Group
2020
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7856134/ https://ncbi.nlm.nih.gov/pubmed/33097621 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2019-001914 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|